US FDA adds haemodialysis bloodlines to devices shortage list
.png)
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
For those with kidney failure, haemodialysis can be a lifesaving treatment that removes waste products and excess fluids from the blood where the kidneys fail to do so. Haemodialysis bloodlines are just one critical component of the haemodialysis machine – they form the specialised tube system connecting a patient’s bloodstream to the haemodialysis machine.
Following a customer letter from German medical and pharmaceutical device manufacturer B. Braun, which outlined a market disruption of 8mm pre-pump bloodlines, the US FDA wrote that they were aware of the interruptions to the supply of haemodialysis bloodlines due to supplier issues. “The disruption in supply of this device is expected to impact patient care and as such may require adjustments to the clinical management of patients receiving acute or chronic haemodialysis,” wrote the US FDA.
The health agency listed several recommendations to healthcare providers on conserving use of the bloodlines and preserving supply. These recommendations included continuing to provide dialysis treatments, monitoring supplies, and developing plans to conserve the supply of bloodlines.
The US FDA also updated its Medica Device Shortages List to include haemodialysis bloodlines. The list aims to provide transparency to the public about shortages of medical devices, especially those involved in the use or purchase of medical devices.
Sources:
1. Disruptions in Availability of Hemodialysis Bloodlines – Letter to Health Care Providers [Accessed March 17, 2025] https://www.fda.gov/medical-devices/letters-health-care-providers/disruptions-availability-hemodialysis-bloodlines-letter-health-care-providers
2. Supply Disruption on FMC Streamline Bloodlines UPDATE [Accessed March 17, 2025] https://www.medline.com/media/assets/pdf/vendor-list/25-0007_Supply_Disrupt_Streamline_Bloodlines_Ltr_FINAL_010825.pdf
Related News
-
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig... -
News Medtech company Beta Bionics targets USD$616 million IPO valuation
California-based insulin delivery device manufacturer Beta Bionics have stated their intentions to target an IPO valuation of USD$616 million in the United States, signalling an optimistic recovery of medtech and biotech public listings.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance